2025
document
A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer . Recombinant human TSH has been developed to facilitate monitoring for thyroid carcinoma recurrence or persistence without the attendant morbidity of hypothyroidism seen after thyroid hormone withdrawal . The objectives of this study were to compare the effect of administered recombinant human TSH with thyroid hormone withdrawal on the results of radioiodine whole body scanning ( WBS ) and serum thyroglobulin ( Tg ) levels . Two hundred and twenty-nine adult patients with differentiated thyroid cancer requiring radioiodine WBS were studied . Radioiodine WBS and serum Tg measurements were performed after administration of recombinant human TSH and again after thyroid hormone withdrawal in each patient . Radioiodine whole body scans were concordant between the recombinant TSH-stimulated and thyroid hormone withdrawal phases in 195 of 220 ( 89 % ) patients . Of the discordant scans , 8 ( 4 % ) had superior scans after recombinant human TSH administration , and 17 ( 8 % ) had superior scans after thyroid hormone withdrawal ( P = 0.108 ) . Based on a serum Tg level of 2 ng/mL or more , thyroid tissue or cancer was detected during thyroid hormone therapy in 22 % , after recombinant human TSH stimulation in 52 % , and after thyroid hormone withdrawal in 56 % of patients with disease or tissue limited to the thyroid bed and in 80 % , 100 % , and 100 % of patients , respectively , with metastatic disease . A combination of radioiodine WBS and serum Tg after recombinant human TSH stimulation detected thyroid tissue or cancer in 93 % of patients with disease or tissue limited to the thyroid bed and 100 % of patients with metastatic disease . In conclusion , recombinant human TSH administration is a safe and effective means of stimulating radioiodine uptake and serum Tg levels in patients undergoing evaluation for thyroid cancer persistence and recurrence .
2026
Intervention_Pharmacological
Recombinant human TSH
2027
Intervention_Pharmacological
administered recombinant human TSH
2028
Intervention_Pharmacological
Radioiodine WBS
2029
Intervention_Pharmacological
recombinant human TSH
2030
Intervention_Pharmacological
recombinant TSH-stimulated
2031
Intervention_Pharmacological
recombinant human TSH administration
2032
Intervention_Pharmacological
thyroid hormone therapy
2033
Intervention_Pharmacological
recombinant human TSH
2034
Intervention_Pharmacological
thyroid hormone withdrawal
2035
Intervention_Pharmacological
recombinant human TSH administration
2036
Outcome_Physical
recombinant TSH-stimulated
2037
Outcome_Physical
thyroid hormone withdrawal phases
2038
Outcome_Physical
serum Tg level
2039
Outcome_Physical
thyroid tissue
2040
Outcome_Physical
cancer
2041
Participant_Sample-size
Two hundred and twenty-nine
2042
Participant_Age
adult
2043
Participant_Condition
patients with differentiated thyroid cancer requiring radioiodine WBS were studied .
2044
Participant_Condition
patients with disease or tissue limited to the thyroid bed